Early Diagnosis of Cardiomyopathies: Saving Lives and Reducing Healthcare Costs in Europe (2025)

Hidden in Plain Sight: The Urgent Push for Early Detection of Cardiomyopathies to Safeguard Europe's Heart Health

Imagine a silent thief stealing lives across Europe, often going unnoticed until it's too late—that's the harsh reality of cardiomyopathies, heart muscle disorders that demand our immediate attention for better cardiovascular outcomes.

Experts involved in the Cardiomyopathies Matter campaign are passionately underscoring the critical need to push forward with earlier identification of these conditions.

Spotting cardiomyopathies early, then providing the right care and ongoing oversight, has the potential to sharply cut down on sudden trips to the emergency room, complex medical procedures, and the ongoing support needed for disabilities that follow.

By Cardiomyopathies Matter (https://www.theparliamentmagazine.eu/news/author/cardiomyopathies-matter)

Cardiomyopathies Matter is a collaborative effort bringing together various stakeholders, supported financially by Bristol Myers Squibb and Philips. Its main goal? To spotlight cardiomyopathies for decision-makers and make sure these serious health issues get the policy spotlight they deserve, both within individual countries and across the European Union.

12 Nov 2025

As members of the Cardiomyopathies Matter (https://cardiomyopathiesmatter.org/about-the-initiative/) campaign, we're championing the development of top-notch policies for heart health at both the European Union and country-specific levels.

Heart-related illnesses, known as cardiovascular diseases (CVDs)—which encompass cardiomyopathies—stand as Europe's biggest health hurdle. Picture this: more than six million fresh diagnoses each year, leading to 1.8 million deaths—that's a staggering one-third of all fatalities in the region. And the financial hit? A whopping €282 billion annually, rippling out from medical bills into lost work hours and extended care needs.1 To put it simply, for beginners, CVDs are like the top enemy of public health here, affecting everyday folks from all walks of life and straining economies everywhere.

Given this enormous strain on people and finances, the European Union is ramping up its efforts on heart health. Just on December 3, 2024, the EU's Health Ministers came together to approve Council Conclusions2 that push for beefed-up prevention strategies and quicker spotting of CVDs. On top of that, the European Commission is gearing up to launch a comprehensive European Cardiovascular Health Plan3. This plan promises to outline ambitious, unified approaches to stopping diseases before they start, catching them early, fostering new innovations, and aiding recovery—all aimed at lightening the load of CVDs throughout Europe, with a special nod to cardiomyopathies.

Now, let's break down cardiomyopathies for those new to the topic: these are a family of disorders affecting the heart's muscle, frequently stemming from genetic factors passed down through families. They weaken the heart's pumping power, turning what should be a vital organ into a ticking time bomb. Despite their severe consequences, these conditions fly under the radar in public health discussions. They touch about 1.5 million lives in Europe,4 ranking high among reasons for unexpected deaths and the need for heart transplants.5 The trouble? Diagnosis often comes too late or wrong altogether. Early signs are sneaky—think everyday tiredness, trouble catching your breath during simple activities, or a vague ache in the chest—which makes it tough for even doctors to catch them right away. For example, someone might brush off shortness of breath as just being out of shape, delaying vital checks.

When cardiomyopathies go undiagnosed for too long, they wreak havoc on individuals' daily lives and can end in tragedy. But catching them soon enough and starting tailored treatments can dramatically lower the chances of emergency visits, high-tech fixes, and lifelong disability support. Since many of these are hereditary, finding it in one person opens the door to checking relatives, spotting risks early, and stopping severe problems from hitting the family. For Europe, making early detection and prevention a priority isn't just smart—it's an essential investment in stronger health, a more productive workforce, and a tougher society overall.

Why Early Detection Matters So Much

Pushing for early spotting of cardiomyopathies isn't merely a medical checkbox; it's a must-have for smart policymaking. The sooner these genetic heart issues are uncovered, the brighter the future looks for those affected, their loved ones, and entire healthcare networks. However, across Europe, there are still big holes in the system that let diagnoses slide until things turn critical or deadly.

Take the OECD's insights6: mistakes in diagnosing conditions eat up to 17.5% of health budgets. Cutting those errors in half could unlock 8% more funds—think hundreds of billions of euros—to tackle other pressing needs. Specifically for cardiomyopathies, sharper diagnostics mean fewer preventable hospital stays, lower ongoing expenses, and, most importantly, lives preserved. Catching it early avoids drastic surgeries, spares years of suffering, and lets more people stay active in their communities and jobs. And this is the part most people miss: early intervention isn't just about saving money; it's about giving families back their futures.

Because the initial warning signs are so mild and easy to ignore—like feeling unusually worn out after a walk—cardiomyopathies often aren't found until they're far along. But when doctors diagnose them promptly, they can roll out precise medications, suggest helpful lifestyle changes, and use preventive tools like implanted devices that shock the heart back into rhythm if needed. These steps slash the odds of full-blown heart failure or sudden cardiac events. In essence, timely detection flips the script on the disease, offering real hope to countless families who might otherwise face heartbreak.

The Hurdles We're Facing

During a recent roundtable we hosted at the European Parliament as part of Cardiomyopathy Awareness Month, it was clear: doctors, patient champions, and lawmakers are uniting around a key idea—making early detection of genetic heart conditions a foundational pillar of EU health strategies.

But here's where it gets controversial: while we all agree on the need, some argue that pouring resources into rare genetic tests diverts funds from more widespread issues like obesity-related heart disease. What do you think—should niche conditions like cardiomyopathies get special policy focus, or is that unfair to broader threats?

Key roadblocks persist, including low knowledge levels among medical staff, patchy availability of cutting-edge scanning tech, and inconsistent rules for genetic exams across borders. These need fixing now.

Fortunately, we have effective options ready to go: for instance, cardiac MRI scans are gold-standard for evaluating different cardiomyopathy types, providing detailed images of the heart's structure without invasive steps. Genetic testing, meanwhile, can be a game-changer, pinpointing who's at risk and allowing whole families to get screened proactively. Yet, these stay sidelined without uniform screening guidelines and funding for training experts. To clarify for newcomers, imagine genetic testing as a family tree scan—it reveals hidden risks before symptoms show, much like a smoke detector before a fire starts.

Beyond the physical toll, cardiomyopathies hit hard on an emotional level: late discoveries disrupt not only bodily functions but also mental health, relationships at home, and chances for normal living. After diagnosis, weaving in counseling for emotional support and connecting people with support groups should be standard in treatment plans, creating care that's truly focused on the whole person.

Time to Step Up: Early Detection Can Save Lives

With the European Union shaping its upcoming health priorities, it's time to turn these ideas into real steps. Cardiomyopathies Matter is calling on the EU to weave early detection of these heart conditions right into the core of its health frameworks, so no one suffers needlessly because their issue stayed hidden too long.

Getting ahead of cardiomyopathies through early checks is crucial for curbing unnecessary fatalities, boosting daily living standards, and making smarter use of health dollars. Speaking as doctors, scientists, and voices for patients, we're pressing EU leaders to move boldly—plug the holes in spotting CVDs broadly and cardiomyopathies specifically, tackle those stubborn barriers, and weave solutions into the European Cardiovascular Health Plan.

Early Diagnosis of Cardiomyopathies: Saving Lives and Reducing Healthcare Costs in Europe (2025)

Read Next: